Fresenius stock trades at EUR 42.65 with a P/ E of 15.5

Published on 10/09/2026 at 16:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius stock stood at EUR 42.65 on October 9, 2026, up 1.96 percent from EUR 41.83. P/E is 15.5 and the range is EUR 35.11 to EUR 52.96.

Key points in brief

Fresenius stock was at EUR 42.65 at Lang & Schwarz on October 9, 2026, up 1.96 percent from EUR 41.83.
The EUR 24.0 billion company trades at a P/E ratio of 15.5, with a 52-week range of EUR 35.11 to EUR 52.96.
Fresenius is scheduled to report third-quarter 2026 results on November 4, 2026, while Jefferies maintains a EUR 55.00 price target.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius stock (ISIN DE000FRE5EN2) was trading at EUR 42.65 at Lang & Schwarz on October 9, 2026 at 4:42 p.m. CEST, up 1.96 percent from the prior close of EUR 41.83. The quote places the healthcare group below its EUR 52.96 52-week high and above its EUR 35.11 low.

Price and trading activity

The primary Xetra quote was EUR 42.66 at 4:32 p.m. CEST on October 9, 2026, according to the latest market data, while trading volume stood at 365,690 shares against an average volume of 989,469. The Lang & Schwarz bid was EUR 42.64 and the ask was EUR 42.67, producing a narrow EUR 0.03 spread.

Fresenius has a market capitalization of EUR 24.0 billion as of October 9, 2026. Its EUR 42.65 price is 19.47 percent below the 52-week high of EUR 52.96 and 21.47 percent above the 52-week low of EUR 35.11.

Valuation and analyst target

The stock's trailing P/E ratio is 15.5 as of October 9, 2026. That valuation sits below Siemens Healthineers at a P/E ratio of 19.7 and above Drägerwerk at 12.6, creating a middle position among the two healthcare peers shown below.

According to wallstreetONLINE on October 5, 2026, Jefferies kept its Buy rating and EUR 55.00 price target for Fresenius. The target lies 28.93 percent above the Lang & Schwarz price, a gap that gives the analyst view a concrete valuation reference without changing the neutral market-report focus.

Comparison with peers

Fresenius: plus 1.96 percent, P/E 15.5, market capitalization EUR 24.0 billion

Siemens Healthineers (Xetra, EUR): plus 1.91 percent, P/E 19.7, market capitalization EUR 43.6 billion

Drägerwerk (Xetra, EUR): plus 3.95 percent, P/E 12.6, market capitalization EUR 2.2 billion

Next reporting date

Fresenius lists November 4, 2026, in Bad Homburg as the date for its third-quarter 2026 conference call. The latest investor-relations page also reports second-quarter 2026 revenue of EUR 5.864 billion, up 6.00 percent organically, core net income of EUR 470 million, up 14.00 percent, and core earnings per share of EUR 0.83, up 14.00 percent.

The further course of trading is shown by the continuously updated real-time quote of Fresenius stock.